Biology Reference
In-Depth Information
IL-6-gp130 signaling. However, the direct interaction of the chi-
meric protein Hyper-IL-6 with gp130, independent of the hetero-
receptor component inducing its prolonged dimerization and
signaling, explains the unique phenotype observed upon adminis-
tration of Hyper-IL-6 to induce tissue regeneration. The genera-
tion of the designer cytokine Hyper-IL-6 made it possible to better
define cell types that, in their IL-6 response, depend on sIL-6R.
Since Hyper-IL-6 is between 100 to 1,000 times more active than
the separate proteins IL-6 and sIL-6R, the stimulation achieved
with Hyper-IL-6 is considerably impressive. Such treatment has
been shown so far to lead to life-saving therapy of animals with
liver and kidney damage with further experiments on the way to
explore the use of HIL-6 in heart and salivary gland regeneration.
References
1. Hirano T et al (1986) Complementary DNA
for a novel human interleukin (BSF-2) that
induces B lymphocytes to produce immuno-
globulin. Nature 324:73-76
2. Bazan JF (1990) Haemopoietic receptors and
helical
12. Müllberg J et al (1993) The soluble interleu-
kin-6 receptor is generated by shedding. Eur
J Immunol 23:473-480
13. Müllberg J et al (1992) Protein kinase C
activity is rate limiting for shedding of the
interleukin-6 receptor. Biochem Biophys Res
Commun 189:794-800
14. Dimitrov S et al (2006) Sleep enhances IL-6
trans-signaling in humans. FASEB J
20(12):2174-2176
15. Scheller J et al (2011) ADAM17: a molecular
switch to control inflammation and tissue
regeneration. Trends Immunol 32:380-387
16. Althoff K et al (2001) Recognition sequences
and structural elements contribute to shed-
ding susceptibility of membrane proteins.
Biochem J 353:663-672
17. Althoff K et al (2000) Shedding of interleu-
kin-6 receptor and tumor necrosis factor
alpha. Contribution of the stalk sequence to
the cleavage pattern of transmembrane pro-
teins. Eur J Biochem 267:2624-2631
18. Matthews V et al (2003) Cellular cholesterol
depletion triggers shedding of the human
interleukin-6 receptor by ADAM10 and
ADAM17
cytokines.
Immunol
Today
11:350-354
3. Yamasaki K et al (1988) Cloning and expres-
sion of the human interleukin-6 (BSF-2/IFN
beta 2) receptor. Science 241:825-828
4. Hibi M et al (1990) Molecular cloning and
expression of an IL-6 signal transducer,
gp130. Cell 63:1149-1157
5. Heinrich PC et al (2003) Principles of inter-
leukin (IL)-6-type cytokine signalling and its
regulation. Biochem J 374:1-20
6. Scheller J et al (2006) Updating IL-6 classic-
and
trans-signaling.
Signal
Transduct
6:240-259
7. Rose-John S et al (2006) Interleukin-6 biol-
ogy is coordinated by membrane-bound and
soluble receptors: role in inflammation and
cancer. J Leukoc Biol 80:227-236
8. Jones S et al (2011) Therapeutic strategies for
the clinical blockade of IL-6/gp130 signal-
ing. J Clin Invest 121:3375-3383
9. Campard D et al (2006) Multilevel regulation
of IL-6R by IL-6-sIL-6R fusion protein
according to the primitiveness of peripheral
blood-derived CD133+ cells. Stem Cells
24:1302-1314
10. Rose-John S, Heinrich PC (1994) Soluble
receptors for cytokines and growth factors:
generation and biological function. Biochem
J 300(Pt 2):281-290
11. Romano M et al (1997) Role of IL-6 and its
soluble receptor in induction of chemokines and
leukocyte recruitment. Immunity 6:315-325
(TACE).
J
Biol
Chem
278:38829-38839
19. Mullberg J et al (1995) A metalloprotease
inhibitor blocks shedding of the IL-6 recep-
tor and the p60 TNF receptor. J Immunol
155:5198-5205
20. Black RA et al (1997) A metalloproteinase
disintegrin that releases tumour-necrosis fac-
tor-alpha from cells. Nature 385:729-733
21. Moss ML et al (1997) Cloning of a disinteg-
rin metalloproteinase that processes precursor
tumour-necrosis factor-alpha. Nature 385:
733-736
Search WWH ::
Custom Search